Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Jiangsu Lianhuan Pharmaceutical Co., Ltd. carries a market capitalization of 4.55B, placing it among publicly traded companies globally. Its enterprise value stands at 4.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.55B |
| Enterprise Value | 4.38B |
Share Statistics
Jiangsu Lianhuan Pharmaceutical Co., Ltd. currently has 285.46M shares outstanding.
| Shares Outstanding | 285.46M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jiangsu Lianhuan Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 23.34. The price-to-sales ratio is 1.25, and the price-to-book ratio stands at 3.00.
| PE Ratio | 23.34 |
| PS Ratio | 1.25 |
| PB Ratio | 3.00 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | 14.34 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jiangsu Lianhuan Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 39.32 and an EV/FCF ratio of 21.59. The EV/Sales ratio of 1.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 39.32 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.89 |
| EV / EBITDA | 39.32 |
| EV / EBIT | 39.32 |
| EV / FCF | 21.59 |
Financial Position
Jiangsu Lianhuan Pharmaceutical Co., Ltd. maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 82.83, indicating elevated leverage, while an interest coverage ratio of 3.89 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.18 |
| Quick Ratio | 0.18 |
| Debt / Equity | 82.83 |
| Debt / EBITDA | 12.61 |
| Interest Coverage | 3.89 |
Financial Efficiency
Jiangsu Lianhuan Pharmaceutical Co., Ltd. posts a return on equity of -1.89 and a return on invested capital of 0.16.
| Return on Equity (ROE) | -1.89 |
| Return on Assets (ROA) | -0.56 |
| Return on Invested Capital (ROIC) | 0.16 |
| Return on Capital Employed (ROCE) | -1.61 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.81 |
Taxes
Over the trailing twelve months, Jiangsu Lianhuan Pharmaceutical Co., Ltd. has paid 34.48M in income taxes, reflecting an effective tax rate of 96.16.
| Income Tax | 34.48M |
| Effective Tax Rate | 96.16 |
Stock Price Statistics
Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s stock has gained approximately 34.14634% over the past 52 weeks. The 50-day moving average sits at 18.28, while the 200-day moving average is 20.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | 34.14634% |
| 50-Day Moving Average | 18.28 |
| 200-Day Moving Average | 20.05 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jiangsu Lianhuan Pharmaceutical Co., Ltd. generated 2.32B in revenue and converted that into -18.76M in net income, yielding earnings per share of 0.00. EBITDA reached 111.26M, while operating income came in at 111.26M.
| Revenue | 2.32B |
| Gross Profit | 991.31M |
| Operating Income | 111.26M |
| Pretax Income | 35.85M |
| Net Income | -18.76M |
| EBITDA | 111.26M |
| EBIT | 111.26M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Jiangsu Lianhuan Pharmaceutical Co., Ltd. holds 281.34M in cash and equivalents against 1.40B in total debt, resulting in a net debt position of 1.08B. Total book value stands at 965.21M, with working capital of 273.46M providing operational flexibility.
| Cash & Cash Equivalents | 281.34M |
| Total Debt | 1.40B |
| Net Debt | 1.08B |
| Equity (Book Value) | 965.21M |
| Book Value Per Share | 3.35 |
| Working Capital | 273.46M |
Cash Flow
After subtracting -201.59M in capital expenditures, free cash flow totaled -201.59M - equivalent to -0.70 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -201.59M |
| Free Cash Flow | -201.59M |
| FCF Per Share | -0.70 |
Margins
Jiangsu Lianhuan Pharmaceutical Co., Ltd. operates with a gross margin of 42.74, reflecting its pricing power and cost economics. The operating margin of 4.80 and net profit margin of -0.81 provide insight into operational efficiency.
| Gross Margin | 42.74 |
| Operating Margin | 4.80 |
| Pretax Margin | 1.55 |
| Profit Margin | -0.81 |
| EBITDA Margin | 4.80 |
Dividends & Yields
The company's payout ratio of 201.47 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.15 |
| Dividend Yield | N/A |
| Payout Ratio | 201.47 |
| Shareholder Yield | -17.70 |
| FCF Yield | 6.97 |
Stock Splits
Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s most recent stock split took place on May 19, 2017 with a 10:13 split ratio.
| Last Split Date | 5/19/2017 |
| Split Ratio | 10:13 |
Scores
Jiangsu Lianhuan Pharmaceutical Co., Ltd. posts an Altman Z-Score of 2.04, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.04 |